Etoricoxib (Arcoxia): recommended starting dose revised

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Etoricoxib, a COX-2 inhibitor has been linked to a possible increase in risk of coronary and cerebrovascular thrombotic events, heart failure, hypertension, and oedema. GI perforation, ulceration, or bleeding are other risks to be considered with etoricoxib therapy.

Trial results have shown that the 60-mg dose is effective...

Recommended for you

  • Drug Updates
  • 1 comment

Do not use Solu-Medrone 40 mg in patients with a known or suspected allergy to cows’ milk

  • Drug Updates
  • 1 comment

Gabapentin (Neurontin): Risk of developing respiratory depression without concomitant use of opioids

  • Drug Updates
  • 1 comment

Isotretinoin (Roaccutane): Risk of sexual side effects like erectile dysfunction and decreased libido

  • Drug Updates
  • 1 comment

Clozapine associated with risk of intestinal obstruction, faecal impaction, and paralytic ileus

  • Drug Updates
  • 1 comment

Loperamide (Imodium): Overdoses of loperamide associated with risk of serious cardiovascular events

  • Drug Updates
  • 1 comment

Patients on warfarin should not use over-the-counter Miconazole oral gel (Daktarin)

  • Drug Updates
  • 1 comment

Revised recommendations for use of adrenaline auto-injectors post European review

  • Drug Updates
  • 1 comment

Local and systemic administration of corticosteroids: risk of central serous chorioretinopathy

  • Drug Updates
  • 1 comment

Ibrutinib (Imbruvica▼): Reported cases of ventricular tachyarrhythmia and risk of hepatitis B reactivation and opportunistic infections

  • Drug Updates
  • 1 comment

Daclizumab (Zinbryta▼) in multiple sclerosis: Review patients for liver function currently on treatment

  • Drug Updates
  • 1 comment

Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): Risk of graft rejection

  • Drug Updates
  • 1 comment

Bendamustine (Levact): Increased mortality when used in combination treatment outside the approved indications

  • Drug Updates
  • 1 comment

Restrictions to manage the risk for misuse of pseudoephedrine and ephedrine to be continued

  • Drug Updates
  • 1 comment

Brimonidine gel (Mirvaso): Risk of cardiovascular events if applied to damaged skin

  • Drug Updates
  • 1 comment

Yellow Card Scheme Website: Report any side effects or safety concerns with e-cigarettes and e-liquids

  • Drug Updates
  • 1 comment

Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

  • Drug Updates
  • 1 comment

Finasteride 1 mg (Propecia): Reports of depression and suicidal thoughts in men

  • Drug Updates
  • 1 comment

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

  • Drug Updates
  • 1 comment

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

  • Drug Updates
  • 1 comment

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

  • Drug Updates
  • 1 comment

Pilot website to report adverse reactions of psychoactive substances

  • Drug Updates
  • 1 comment

Canagliflozin (Invokana▼): Increased risk of lower limb amputation

  • Drug Updates
  • 1 comment

Posaconazole (Noxafil): tablets and oral suspension not interchangable

  • Drug Updates
  • 1 comment

Levonorgestrel-containing emergency contraceptives: interaction with hepatic enzyme inducers

  • Drug Updates
  • 1 comment

Idelalisib (Zydelig▼): updated safety information on risk of infection

  • Drug Updates
  • 1 comment

Lonsurf ▼(trifluridine/tipiracil) approved for colorectal cancer chemotherapy

  • Drug Updates
  • 1 comment

Riociguat (Adempas) contraindicated in pulmonary hypertension associated with idiopathic interstitial pneumonias

  • Drug Updates
  • 1 comment

Suspected fatal drug interaction between citalopram and cocaine

  • Drug Updates
  • 1 comment

N-acetylcysteine interference with Siemens assays: false-low test results

  • Drug Updates
  • no comment

Rare reports of calciphylaxis in patients taking warfarin